Previous 10 | Next 10 |
Galapagos (GLPG) announces interim results from MANTA and MANTA-RAy, two ongoing safety studies investigating the effect of Jyseleca (filgotinib) on sperm parameters in males with inflammatory bowel disease ((MANTA)) or rheumatic conditions (MANTA-RAy). In total, 248 patients were random...
8.3% patients on placebo and 6.7% patients on filgotinib had a 50% or more decline in sperm concentration at week 13 No new safety findings were identified Data will be submitted to the relevant regulatory authorities Mechelen, Belgium, 4 March 2021, 07.4...
Mechelen, Belgium; 3 March 2021; 22.15 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc. Pursuant to Belgian transparency legislation 1 , Galapagos received a transpare...
BiotechValley Insights is initiating coverage of ACRS with a "Bullish" rating. ATI-450 is a novel oral MK2 inhibitor that demonstrated comparable efficacy and superior safety over Jak inhibitors during Ph2. The oral route of administration offers a superior convenience over biological...
Galapagos NV (GLPG) Q4 2020 Earnings Conference Call February 19, 2021 8:00 AM ET Company Participants Elizabeth Goodwin - Vice President, Investor Relations Onno van de Stolpe - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer Walid Abi-Saab - Chief...
Image source: The Motley Fool. Galapagos NV (NASDAQ: GLPG) Q4 2020 Earnings Call Feb 19, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Galapagos NV (GLPG) Q4 2020 Earnings Call Transcript
Announcing its full-year financial results for 2020, Galapagos NV ([[GLPG]] +2.4%) recorded a 40.2% YoY decline in Group revenues to €530M compared to ~176.0% YoY growth in 2019. Net loss reached €305M from €150M of profit in 2019.The company attributed the reve...
Key 2020 events: Jyseleca approved for rheumatoid arthritis (RA) in Europe & Japan Gilead decided not to pursue the RA indication in the U.S. as a result of Complete Response Letter (CRL) from the Food and Drug Administration (FDA) Galapagos to assume commercialization...
bluebird bio (BLUE) -30% after suspending sickle cell disease trial.Hepion Pharmaceuticals (HEPA) -28% after pricing stock offering.Cortexyme (CRTX) -26% after regulatory update on Atuzaginstat in Alzheimer’s Disease.Neptune Wellness Solutions (NEPT) -21%&...
A large part of a $5 billion bet that Gilead Sciences (NASDAQ: GILD) made in 2019 has fallen apart in late clinical-stage development. The bottom fell out from under ziritaxestat, a new drug candidate Gilead Sciences was developing in partnership with Galapagos (NASDAQ: GLPG) ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...